The only study that put BPC-157 and TB-500 head to head on a cut tendon used 32 rats. Only TB-500 beat the controls on strength, the two peptides didn’t differ from each other, and stacking them added nothing.
No human trial has compared them. This page covers that rat study, what each peptide has behind it, and where both stand with FDA and WADA.
Quick takeaways
| Question | What the evidence shows |
|---|---|
| Has any human trial compared them? | No. |
| What did the only comparison find? | In rats with a cut Achilles tendon, only TB-500 beat the vehicle controls on strength. TB-500 and BPC-157 didn’t differ from each other, and the combination added nothing (1). |
| Does either have human tendon data? | BPC-157 has one small retrospective case series. TB-500 has none (2). |
| Is TB-500 the same as thymosin beta-4? | No. TB-500 is a seven-amino-acid fragment of the 43-amino-acid peptide (2, 3, 4). |
| Are they approved? | Neither has an FDA-approved musculoskeletal use (2). FDA lists both among withdrawn bulk-drug nominations (4). In July 2026 FDA staff proposed that neither be added to the compounding bulks list (11), and press reports say the advisory committee voted 8 to 6 to recommend both anyway (12). The vote is advisory, and no rule has been issued. WADA prohibits both (9, 10). |
| Where are the doses? | No dose or schedule has been validated in people for tendon healing, so this page lists none. |
The only head-to-head study
In 2026, Biçer and colleagues cut and repaired the Achilles tendons of 32 rats. Eight rats each got BPC-157, TB-500, both or a vehicle injection, once a day into the abdominal cavity for four weeks (1).
TB-500 was the only group with significantly higher strength than controls (adjusted p=0.0406). BPC-157 and TB-500 didn’t differ from each other: the medians were 37.2 and 37.4 N against 26.9 N for controls. TB-500 also had significantly better tendon-structure scores than controls. BPC-157 was numerically better than control on both, but didn’t reach significance on total scores. The combination beat control on one structure score (p=0.040) and added nothing over either peptide alone (1).
| Group | Strength test (load to failure) | Tendon structure scores (lower is better) |
|---|---|---|
| BPC-157 | Higher than control, not significant | Numerically lower, not significant on totals |
| TB-500 | Significantly higher (p<0.05) | Significantly lower (Bonar p=0.016, Movin p=0.017) |
| BPC-157 + TB-500 | Median 34.5 N, not different from any group | Movin p=0.040, with no added benefit over either alone |
The authors call it exploratory. Strength testing used 4 tendons per group, and the other 4 went to histology. Follow-up was four weeks. The pathologist and the strength testers were blinded, but surgery and dosing weren’t, and there was no a priori power calculation. The paper calls the TB-500 a synthetic peptide derived from thymosin beta-4, and it doesn’t say whether it was the seven-amino-acid fragment (1). The authors suggest the lack of an added effect may reflect shared downstream pathways, and say that idea needs testing (1).
What BPC-157 has
BPC-157 is a 15-amino-acid peptide. In rats with a transected Achilles tendon, daily BPC-157 improved load to failure, function and tendon structure compared with saline (5). That’s a rat result.
The human evidence is thin. A 2026 JAAOS review found one small retrospective, uncontrolled case series for musculoskeletal use (2). A separate 2026 systematic review found three human studies covering 30 people, none a controlled trial. It rated the certainty very low (6). A 2025 review of orthopaedic use found 36 studies, 35 of them preclinical (7).
FDA says it found no or only limited safety information for the routes proposed (4). USADA says WADA prohibits BPC-157 as a non-approved substance (9). Our BPC-157 guide goes deeper.
What TB-500 has
TB-500 isn’t thymosin beta-4. Doping-control chemists identified a TB-500 product as Ac-LKKTETQ, the seven-amino-acid fragment of thymosin beta-4 (residues 17 to 23) (3). Thymosin beta-4 is a 43-amino-acid peptide (8). The 2026 JAAOS review notes the fragment is often conflated with full-length thymosin beta-4, with no validated equivalence (2).
Direct musculoskeletal evidence for thymosin beta-4 is limited to cell and rodent studies (2). Thymosin beta-4 is also overexpressed in colorectal cancer tissue and, in cells, increased invasion and migration (8). Whether the TB-500 fragment does anything in people is unknown.
FDA says it has found no human exposure data on drug products containing the fragment (4). WADA prohibits TB-500 under S2 (10). Our TB-500 guide covers the details.
Doses, injection sites and timelines
No dose, injection site, schedule, sequence or timeline has been validated in people for either peptide, and this page lists none. No human trial shows that either one speeds tendon healing. The 2026 JAAOS review concludes that routine clinical use can’t currently be recommended (2).
Safety and quality
Human safety data barely exist. The BPC-157 review rated its 30-person evidence very low certainty (6). For products sold as these peptides, the JAAOS review raises concerns about identity, purity, concentration, sterility and manufacturing consistency (2). Anyone considering either, and especially anyone with a cancer history, should talk to a clinician first.
If you’re still comparing options
A certificate of analysis shows what one lot contained. See how to verify a peptide COA, then compare sellers.
Compare sellers by lab report
Research-use products. A lab report describes one lot. It doesn’t make a vial safe to use.
For related reading, see our guide to peptides for joint pain, peptides for tendon repair guide and the KLOW peptide guide, a blend that includes both peptides.
Frequently Asked Questions
Which peptide repairs tendons faster?
No human trial has compared them. In the one rat study that did, only TB-500 beat the controls on the strength test, and it didn’t differ significantly from BPC-157 (1).
Can I use BPC-157 and TB-500 together?
No human trial has tested the combination, so there’s no evidence of benefit or safety. In the rat study, it added nothing over either peptide alone (1).
Which works better for Achilles tendon injuries?
In rats, both have shown benefit on some tendon measures against controls (1, 5). In the one study that compared them, only TB-500 beat controls on strength, and the two didn’t differ from each other (1). Neither has been tested on human Achilles tendons in a controlled trial (2, 6).
How long until I see results?
No human trial gives a timeline for either peptide.
Are there side effects?
Human safety data barely exist (6). FDA found no or only limited safety information on BPC-157 and no human exposure data on the TB-500 fragment (4).
Can peptides replace physical therapy?
No human trial shows either peptide speeds tendon healing, so nothing here replaces rehabilitation or a clinician’s care (2).
Are BPC-157 and TB-500 banned in sport?
WADA prohibits TB-500 under S2 (10), and USADA says BPC-157 is prohibited as a non-approved substance (9).
How do I know a vial is legitimate?
A certificate of analysis from an independent lab that matches your lot number shows what one lot contained. The JAAOS review flags concerns about identity, purity, concentration, sterility and consistency in these products (2).
References
- Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-37. doi:10.52312/jdrs.2026.2951
- Tham A, Hodgkins CW, Kennedy JG. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg. 2026. doi:10.5435/JAAOS-D-26-00049
- Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. doi:10.1002/dta.1402
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks
- Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-83. doi:10.1016/S0736-0266(03)00110-4
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). doi:10.52628/92.3.15837
- Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-95
- Piao Z et al. Thymosin beta4 induces invasion and migration of human colorectal cancer cells through the ILK/AKT/beta-catenin signaling pathway. Biochem Biophys Res Commun. 2014;452(3):858-64. doi:10.1016/j.bbrc.2014.09.012
- USADA. BPC-157: experimental peptide creates risk for athletes
- WADA 2026 Prohibited List, section S2, as reproduced by DSHS Cologne.
- FDA. Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026: FDA briefing document.
- Pharmaceutical Executive. Coverage of the July 2026 FDA advisory committee vote on peptides for compounding.
